Mark Klempner to Middle Aged
This is a "connection" page, showing publications Mark Klempner has written about Middle Aged.
Connection Strength
0.121
-
Wormser GP, Kaslow R, Tang J, Wade K, Liveris D, Schwartz I, Klempner M. Association between human leukocyte antigen class II alleles and genotype of Borrelia burgdorferi in patients with early lyme disease. J Infect Dis. 2005 Dec 01; 192(11):2020-6.
Score: 0.020
-
Klempner MS, Wormser GH, Wade K, Trevino RP, Tang J, Kaslow RA, Schmid C. A case-control study to examine HLA haplotype associations in patients with posttreatment chronic Lyme disease. J Infect Dis. 2005 Sep 15; 192(6):1010-3.
Score: 0.019
-
Kaplan RF, Trevino RP, Johnson GM, Levy L, Dornbush R, Hu LT, Evans J, Weinstein A, Schmid CH, Klempner MS. Cognitive function in post-treatment Lyme disease: do additional antibiotics help? Neurology. 2003 Jun 24; 60(12):1916-22.
Score: 0.017
-
Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, Norton D, Levy L, Wall D, McCall J, Kosinski M, Weinstein A. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med. 2001 Jul 12; 345(2):85-92.
Score: 0.015
-
Perides G, Charness ME, Tanner LM, P?ter O, Satz N, Steere AC, Klempner MS. Matrix metalloproteinases in the cerebrospinal fluid of patients with Lyme neuroborreliosis. J Infect Dis. 1998 Feb; 177(2):401-8.
Score: 0.011
-
Tang KS, Klempner MS, Wormser GP, Marques AR, Alaedini A. Association of immune response to endothelial cell growth factor with early disseminated and late manifestations of Lyme disease but not posttreatment Lyme disease syndrome. Clin Infect Dis. 2015 Dec 01; 61(11):1703-6.
Score: 0.010
-
Chandra A, Wormser GP, Klempner MS, Trevino RP, Crow MK, Latov N, Alaedini A. Anti-neural antibody reactivity in patients with a history of Lyme borreliosis and persistent symptoms. Brain Behav Immun. 2010 Aug; 24(6):1018-24.
Score: 0.007
-
Klempner MS, Styrt B. Prevention of recurrent staphylococcal skin infections with low-dose oral clindamycin therapy. JAMA. 1988 Nov 11; 260(18):2682-5.
Score: 0.006
-
Lin B, Noring R, Steere AC, Klempner MS, Hu LT. Soluble CD14 levels in the serum, synovial fluid, and cerebrospinal fluid of patients with various stages of Lyme disease. J Infect Dis. 2000 Mar; 181(3):1185-8.
Score: 0.003
-
Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL, Sabetta JR, Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE. A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium. N Engl J Med. 1998 Jul 23; 339(4):216-22.
Score: 0.003
-
McDermott DF, Trehu EG, Mier JW, Sorce D, Rand W, Ronayne L, Kappler K, Clancy M, Klempner M, Atkins MB. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor. Clin Cancer Res. 1998 May; 4(5):1203-13.
Score: 0.003
-
Friedberg MH, Glantz MJ, Klempner MS, Cole BF, Perides G. Specific matrix metalloproteinase profiles in the cerebrospinal fluid correlated with the presence of malignant astrocytomas, brain metastases, and carcinomatous meningitis. Cancer. 1998 Mar 01; 82(5):923-30.
Score: 0.003
-
Du Bois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klempner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB. Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. J Clin Oncol. 1997 Mar; 15(3):1052-62.
Score: 0.003
-
Trehu EG, Mier JW, Dubois JS, Sorce D, Klempner MS, Epstein M, Dinarello CA, Shapiro L, Kappler K, Ronayne L, Atkins MB. Phase I trial of interleukin 2 in combination with the soluble tumor necrosis factor receptor p75 IgG chimera. Clin Cancer Res. 1996 Aug; 2(8):1341-51.
Score: 0.003